Clinical-Stage Companies / Alachua Government Services

Alachua Government Services

Pre-Approval PRO BETA

🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 1/1/2023

Total Trials

Phase 3

Phase 2

Recruiting

307

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Influenza Pandemic Influenza Healthy Seasonal Influenza Prophylaxis of Ross River Virus Infection

Clinical Trials (25)

NCT00782431 Phase 3 COMPLETED

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Started: 11/1/2008

NCT00800605 Phase 3 COMPLETED

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Started: 12/1/2008

NCT01773928 Phase 3 COMPLETED

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

Started: 1/1/2013

NCT04705844 Phase 3 WITHDRAWN

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

Started: 9/1/2021

NCT01157702 Phase 3 COMPLETED

Yearly Strain Variation Study, 2010/2011

Started: 7/1/2010

NCT00943657 Phase 3 COMPLETED

Yearly Strain Variation Study, 2009/2010

Started: 6/1/2009

NCT01242670 Phase 3 COMPLETED

Ross River Virus (RRV) Vaccine Study

Started: 4/1/2011

NCT00711295 Phase 3 COMPLETED

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Started: 8/1/2008

NCT01063088 Phase 3 COMPLETED

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Started: 2/1/2010

NCT01604746 Phase 3 COMPLETED

Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801

Started: 7/1/2012

NCT01911754 Phase 3 COMPLETED

Japanese Pediatric H5N1 Vaccine Study

Started: 8/1/2013

NCT01774032 Phase 3 COMPLETED

H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older

Started: 3/1/2013

NCT05142527 Phase 2 WITHDRAWN

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19

Started: 1/1/2023

NCT01382329 Phase 2 COMPLETED

H5N1 Vaccine Study in Japanese Adults

Started: 6/1/2011

NCT04592549 Phase 1 COMPLETED

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19

Started: 12/4/2020

NCT04171115 Phase 1 COMPLETED

Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects

Started: 6/1/2020

NCT01320696 Phase 1 COMPLETED

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Started: 3/1/2011

NCT03046550 Phase 1 COMPLETED

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

Started: 3/20/2017

NCT01258062 Phase 1 COMPLETED

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Started: 9/1/2010

NCT00895544 Phase 1 COMPLETED

Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults

Started: 5/1/2009

NCT00959465 Phase 1 COMPLETED

A/H1N1 Immunogenicity and Safety in Adults

Started: 8/1/2009

NCT00783926 Phase 1 COMPLETED

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Started: 7/1/2008

NCT00717834 Phase 1 COMPLETED

Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine

Started: 6/1/2008

NCT01052402 Phase 1 COMPLETED

Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents

Started: 12/1/2009

NCT00976469 Phase 1 COMPLETED

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Started: 9/1/2009

Drug Candidates

Vero cell derived, trivalent, seasonal influenza vaccine Licensed egg-derived, trivalent seasonal influenza vaccine Vero cell-derived, trivalent, seasonal influenza vaccine Placebo: Phosphate-buffered saline Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified) VCIV manufactured with the current manufacturing process (VCIV current) Fluzone®, licensed trivalent influenza vaccine (TIV) ADM03820 G03-52-01 Placebo

Activity Status: Stale

Last Trial Started: 1/1/2023

Last Trial Ended: 10/6/2023

Trials (12 months): 0

Completed Trials: 23

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.